AI Agents for Allergy and Immunology Practices: Automating Billing From Allergy Testing to Immunotherapy and Biologics in 2026

A single allergy testing session generates 40–80 individual billable units. Each percutaneous prick applied to a patient's skin is one unit of 95004. Each intradermal follow-up on a negative prick result is one unit of 95024. A comprehensive environmental and food panel can produce 60+ test units in a 45-minute session — making allergy testing one of the highest-volume per-encounter billing events in outpatient medicine.

The problem: most allergy practices undercount. The testing technician applies 72 pricks, the biller enters 60 because the handwritten testing sheet is illegible or the EHR template defaults to a standard panel size. Twelve missed units at $4–$6 each is $48–$72 lost — per patient, per session. Multiply that across 2,000–4,000 annual testing sessions and the gap is $50K–$150K before you even reach immunotherapy, biologics, or drug challenges.

The 2026 billing environment makes this worse. Biologic prescribing in allergy is accelerating — omalizumab (Xolair) for severe asthma and chronic urticaria, dupilumab (Dupixent) for atopic dermatitis and eosinophilic esophagitis, mepolizumab and benralizumab for severe eosinophilic asthma. Each biologic carries its own dosing complexity, buy-and-bill margin calculation, and prior authorization burden. UHC's $3B AI audit investment is targeting allergy testing patterns — flagging practices whose test counts per session exceed statistical norms without supporting documentation. The 30–40% annual billing staff turnover (HFMA 2026) hits allergy practices especially hard because immunotherapy billing requires tracking compounding dates, vial inventories, and multi-year treatment courses that a new hire takes months to learn.

AI agents automate every revenue category in allergy billing — from test counting to immunotherapy dose tracking to omalizumab buy-and-bill — and they do it with the precision that eliminates the seasonal staffing crunch when spring and fall testing volumes surge 30–50%.

Allergy Testing: The High-Volume Charge Capture Problem

Allergy testing billing is structurally unlike most medical procedures. Instead of one CPT code per encounter, a single testing session generates dozens of individual units across multiple testing modalities. The coding depends on the method, the number of tests applied, and whether follow-up intradermal testing was performed.

The first error pattern is undercounting percutaneous tests. A standard aeroallergen panel includes trees (8–12 species), grasses (5–8), weeds (5–8), molds (8–12), dust mites (2), animal danders (3–5), and controls (positive histamine, negative saline) — totaling 35–50 individual pricks. Add a food panel (peanut, tree nuts, milk, egg, wheat, soy, shellfish, fish, sesame — 15–25 items), and the session reaches 60–75 units of 95004. When the biller rounds down to the "standard" 50 because the testing form doesn't itemize each allergen, the practice loses $40–$150 per session.

The second error pattern is missing the intradermal follow-up. When percutaneous results are negative or equivocal for clinically suspected allergens, intradermal testing (95024) provides higher sensitivity. These are separate, additional charges — not replacements for the prick tests. A patient who receives 60 prick tests and then 15 intradermal follow-ups should generate 60 units of 95004 plus 15 units of 95024. Billers who replace the prick test charges with intradermal charges instead of adding them lose the entire 95004 revenue for that session.

The third error pattern is modifier -25 on same-day E/M. When the allergist evaluates the patient, reviews history, selects the testing panel, and develops a treatment plan on the same day as testing, the E/M service (99202–99215) is separately billable with modifier -25. But the documentation must support a separately identifiable evaluation — not just "patient here for allergy testing." Practices that skip modifier -25 because they're unsure the documentation qualifies leave $80–$180 per testing encounter unbilled. Practices that apply it without sufficient documentation face audit recoupment.

AI agents solve all three by parsing the testing record against the allergen panel database, counting every individual test applied, validating that intradermal tests are billed as additions (not replacements), and analyzing the E/M note for modifier -25 eligibility. When the documented test count doesn't match the standard panel configuration, AI flags the discrepancy for the testing technician to confirm before the claim is submitted.

Immunotherapy Billing: Two Revenue Streams That Most Practices Mismanage

Allergen immunotherapy (allergy shots) generates revenue from two distinct billing events that occur at different times — and practices consistently confuse them, leaving one or both partially captured.

Stream 1: Antigen Preparation (95165)

When the practice compounds a new immunotherapy treatment set, each dose prepared is one unit of 95165. A typical treatment set consists of 2–3 vials (grouped by allergen compatibility) with 10–12 doses per vial. That's 20–36 units of 95165 billed at the time of compounding — not at the time of each injection. At $8–$12 per unit (Medicare), a single compounding event generates $160–$430 in antigen preparation charges.

For venom immunotherapy (bee, wasp, yellow jacket, hornet, fire ant), the antigen preparation codes differ — 95144 for single stinging insect venom, 95145 for each additional venom. A patient receiving immunotherapy for three venom sensitivities generates 95144 × 1 plus 95145 × 2 per preparation set.

The billing gap: many practices bill 95165 only once at treatment initiation and forget to rebill when refill vials are compounded every 3–6 months. Over a 3–5 year maintenance course, a single immunotherapy patient requires 6–10 compounding events. Missing even two of those events per patient across 500 immunotherapy patients costs $80K–$200K annually.

Stream 2: Injection Administration (95115/95117)

Each injection visit generates a separate administration charge:

• 95115 — Single injection: $24–$32 Medicare rate
• 95117 — Two or more injections: $38–$48 Medicare rate

Most immunotherapy patients receive 2–3 injections per visit (one per vial), which means 95117 is the correct code for the vast majority of injection visits. But billers who default to 95115 because the patient received "their allergy shot" (singular) undercharge by $14–$16 per visit. During the build-up phase (weekly visits for 30–40 weeks), that error costs $420–$640 per patient. During maintenance (monthly visits for 3–5 years), it costs $504–$960 per patient. Across 500 immunotherapy patients, defaulting to 95115 instead of 95117 costs $50K–$100K annually.

AI agents track vial compounding dates, calculate refill timing based on injection frequency, generate 95165 charges when new vials are mixed, and select 95115 versus 95117 based on the number of injections documented at each visit. AI also flags when a patient's build-up schedule has stalled (missed appointments that extend the build-up phase beyond protocol), which affects both clinical outcomes and the revenue timeline.

An allergy practice managing 800 immunotherapy patients that correctly bills both antigen preparation and multi-injection administration recovers $30K–$80K annually compared to practices that bill inconsistently across these two revenue streams.

Omalizumab Buy-and-Bill: The Dosing Table That Breaks Manual Billing

Omalizumab (Xolair) is the most complex drug billing challenge in allergy practice. Unlike most injectables where the dose is weight-based with a simple calculation, omalizumab uses a two-variable dosing matrix — body weight and baseline total serum IgE level — to determine both the dose per injection and the injection frequency.

The dosing table for moderate-to-severe persistent asthma spans:

• Weight range: 20–150 kg across multiple tiers
• IgE range: 30–1,500 IU/mL across multiple tiers
• Dose output: 150 mg to 375 mg per injection
• Frequency output: Every 2 weeks or every 4 weeks
• Maximum monthly dose: 750 mg (varies by weight/IgE intersection)

A 75 kg patient with a baseline IgE of 200 IU/mL receives 300 mg every 4 weeks. That's 60 units of J2357 (per 5 mg). The same 75 kg patient with IgE of 500 IU/mL receives 375 mg every 2 weeks — 75 units of J2357, twice per month. Getting the wrong cell in the dosing table changes the billable amount by hundreds of dollars per encounter and the encounter frequency by 100%.

For chronic spontaneous urticaria (CSU), the dosing is simpler — 150 mg or 300 mg every 4 weeks regardless of IgE — but billers who apply the asthma dosing table to CSU patients (or vice versa) generate claims that don't match the FDA-approved indication, triggering medical necessity denials.

Waste Capture on Omalizumab

Omalizumab comes in 150 mg prefilled syringes and 202 mg (150 mg reconstituted) lyophilized vials. When the prescribed dose doesn't align with available vial sizes, waste occurs. A 225 mg dose requires two 150 mg vials (300 mg total), leaving 75 mg of waste. At approximately $800 per 150 mg vial, unbilled waste on J2357-JW costs $400 per encounter. Across 50–200 omalizumab patients receiving injections every 2–4 weeks, uncaptured waste costs $40K–$120K annually.

AI agents automate the dosing table lookup by pulling the patient's weight and baseline IgE from the EHR, calculating the correct dose and frequency, generating the accurate J2357 unit count, and billing J2357-JW for any vial waste. When a patient's weight changes by more than 5 kg or IgE is retested, AI recalculates and updates the billing parameters. AI also differentiates asthma indication dosing from CSU indication dosing by reading the diagnosis codes on the encounter — preventing the cross-indication billing error that triggers denials.

Drug and Food Challenges: Time-Based Revenue Most Practices Leave on the Table

Oral drug challenges and graded oral food challenges are among the highest-reimbursement office procedures in allergy — but they're also among the most frequently underbilled because of time-based coding complexity.

The coding structure:

• 95076 — Ingestion challenge, initial 120 minutes of direct physician or qualified provider supervision: $180–$250 Medicare rate
• 95079 — Each additional 60 minutes: $90–$130 per unit

A standard graded oral food challenge (peanut, tree nut, milk, egg) involves 5–7 escalating doses given over 3–5 hours, followed by a 1–2 hour observation period. A 4-hour challenge generates 95076 (first 120 min) plus 2 units of 95079 (minutes 121–240), totaling $360–$510. A 5-hour challenge adds a third unit of 95079, reaching $450–$640.

The revenue gap: most practices bill only 95076 because the biller doesn't extract the total challenge duration from the documentation. The add-on units of 95079 — where a single challenge can generate $180–$390 in additional revenue — go unbilled. For a practice performing 300 challenges annually and missing an average of 1.5 add-on units per challenge, the lost revenue is $40K–$60K.

Drug desensitization procedures (95180) present a separate billing opportunity for patients requiring medications they're allergic to — typically antibiotics or chemotherapy agents. These procedures run 4–8 hours under close supervision and generate substantial professional fee revenue when documented correctly.

AI agents extract start and stop times from challenge documentation, calculate the total supervised time, generate the correct number of 95079 add-on units, and validate that the supervising provider's direct involvement is documented for each time increment. AI also captures the separately billable E/M service (modifier -25) when the allergist performs a pre-challenge evaluation and post-challenge management plan.

Spirometry and Diagnostic Testing: Bundling Rules That Trip Up Allergy Billers

Most allergy practices perform in-office spirometry for asthma management, and many add exhaled nitric oxide (FeNO) testing. The billing complexity lies in CCI bundling edits and component coding that allergy-specific billers frequently get wrong.

Spirometry Bundling

The critical rule: 94060 (spirometry before and after bronchodilator) includes 94010 (simple spirometry). When an asthmatic patient gets pre- and post-bronchodilator spirometry, the correct code is 94060 alone — not 94010 + 94060. Billing both triggers a CCI edit denial and, in audit situations, flags the practice for systematic upcoding.

Conversely, when a patient receives only pre-bronchodilator spirometry (no bronchodilator challenge), 94010 is correct. Billers who default to 94060 for every spirometry encounter are upcoding on patients who didn't receive bronchodilator testing.

Additional spirometry codes add revenue when appropriately documented:

• 94070 — Bronchospasm provocation evaluation (methacholine or exercise challenge): separately billable when performed as a distinct diagnostic procedure, not during routine bronchodilator testing
• 94375 — Respiratory flow-volume loop: separately billable when the loop is specifically interpreted and reported beyond the standard spirometry tracing
• 94726 — Plethysmography (lung volumes): separately billable but mutually exclusive with 94727 (gas dilution lung volumes)

FeNO Testing

Fractional exhaled nitric oxide (95012) measures airway inflammation and is used to guide asthma controller therapy — particularly biologic prescribing decisions. At $25–$40 per test, it's modest revenue individually. But for practices performing FeNO on every moderate-to-severe asthma visit (4–6 times per year per patient, 200–500 asthma patients), annual FeNO revenue reaches $20K–$120K when captured consistently.

The gap: FeNO is often performed by the medical assistant as part of the pre-visit workup but never makes it to the billing team because it's documented in the vitals section rather than the procedure section of the encounter. AI agents scan encounter documentation for FeNO results — regardless of where they're recorded in the chart — and generate the 95012 charge automatically.

AI validates spirometry coding against bronchodilator documentation (94060 only when pre- and post-bronchodilator results exist), prevents 94010 + 94060 bundling violations, captures FeNO charges from vitals documentation, and applies correct CCI edits across the complete diagnostic panel. For practices with 200–500 asthma patients, correct spirometry and FeNO charge capture recovers $10K–$30K annually.

Prior Authorization: The Biologic Gatekeeper That Consumes Staff Hours

Every biologic prescribed by an allergist carries a prior authorization requirement with step therapy documentation. The standard pathway varies by drug and indication:

• Omalizumab (asthma): Documented failure of ICS/LABA combination therapy, spirometry confirming persistent airflow obstruction, IgE level within prescribing range, positive aeroallergen sensitivity
• Omalizumab (CSU): Documented failure of H1-antihistamine therapy at up to 4× standard dose, symptom documentation with urticaria activity score
• Dupilumab (atopic dermatitis): Documented failure of topical corticosteroids and/or calcineurin inhibitors, disease severity scoring (EASI, IGA)
• Mepolizumab/benralizumab (eosinophilic asthma): Blood eosinophil count above payer-specific threshold (typically ≥150 or ≥300 cells/μL), documented exacerbation history on ICS/LABA, oral corticosteroid dependence documentation

Each PA submission consumes 30–60 minutes of staff time. Renewals every 6–12 months require updated documentation. For a practice with 100–300 biologic patients across multiple agents, PA management alone requires 0.5–1.0 FTE of dedicated staff time.

AI agents assemble PA packages by extracting the required clinical data from the EHR — spirometry results, eosinophil counts, IgE levels, medication trial history, disease severity scores — mapping it to each payer's step therapy criteria, and pre-populating the authorization form. When PAs approach expiration, AI initiates renewal 30 days in advance, preventing the treatment gap that occurs when a patient arrives for their scheduled injection and discovers authorization has lapsed. For practices managing 100–300 biologic patients, AI-driven PA automation saves 0.5 FTE ($25K–$40K in staffing) and prevents 10–20 annual treatment gaps that each cost $1,000–$3,000 in rescheduling and disease flare management.

What AI Billing Automation Looks Like in an Allergy Practice

AI agents for allergy practices integrate with the practice's EHR (ModMed, athenahealth, eClinicalWorks, Epic, NextGen, or specialty platforms like Medisoft) and allergy-specific testing and immunotherapy management modules. The workflow runs continuously:

1. Per testing session: AI counts every prick and intradermal test from the testing record, matches the count to the allergen panel configuration, generates 95004 and 95024 units, validates modifier -25 on same-day E/M, and flags discrepancies for technician confirmation
2. Per immunotherapy compounding: AI tracks vial inventory and refill schedules, generates 95165 units when new treatment sets are mixed, and ensures compounding charges are captured at time of mixing
3. Per injection visit: AI selects 95115 or 95117 based on documented injection count, captures the administration charge, and updates the treatment course tracking (build-up phase position, maintenance schedule)
4. Per biologic encounter: AI applies the omalizumab dosing table, calculates J2357 units, captures waste on -JW, and verifies the indication-specific dosing protocol matches the diagnosis codes
5. Per challenge: AI extracts total supervised time, generates 95076 plus the correct number of 95079 add-on units, and captures modifier -25 on the separately identifiable E/M
6. Weekly: AI scans upcoming biologic injection schedules against PA expiration dates, initiates renewals 30 days before expiration, and flags immunotherapy patients whose build-up schedules have stalled
7. Monthly: AI reconciles omalizumab acquisition cost against reimbursement, identifies vial inventory variances, and produces compounding charge capture audit reports

Deployment takes 3–6 weeks. The first phase connects to the EHR and allergy testing module, maps the immunotherapy and biologic patient panels, and runs a retrospective audit of the prior 90 days to quantify current revenue leakage. Most practices see the first measurable impact — corrected test counts and captured compounding charges — within 30 days.

The Financial Case: What Allergy Practices Recover

For a practice with 3–6 allergists managing 3,000–8,000 active patients (including 500–2,000 immunotherapy patients and 50–200 biologic patients), the annual revenue recovery from AI billing automation breaks down:

The ROI calculation is direct. AI billing automation costs a fraction of the seasonal temp staff allergy practices hire for spring and fall testing surges ($15K–$25K per season in temp billing support) and eliminates the multi-year immunotherapy tracking burden that drives experienced billers to leave for less complex specialties. Most practices see full ROI within 60 days.